D&D Pharmatech announced on the 16th that it has signed a research service contract with Pfizer in the United States for the development of an oral peptide dual agonist (obesity treatment) formulation.



The contract amount is equivalent to 42.64% of last year’s sales. The contract period runs until November 30, 2026.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing